论文部分内容阅读
目的:观察博利康尼、布地奈德、氨溴索联合雾化吸入对阻塞性肺疾病急性加重期(AECPD)的临床疗效。方法:将72例AECPD患者随机分为两组,治疗组和对照组各36例。治疗组在吸氧、抗感染等治疗的基础上加博利康尼、布地奈德、氨溴索联合氧气驱动雾化吸入,每天2次;对照组在吸氧、抗感染等治疗的基础上用博利康尼、氨溴索口服。记录两组患者用药7天前后咳嗽、气短或喘息、痰液等方面的变化。结果:两组疗效相比有显著性差异(P<0.05)。结论:博利康尼、布地奈德、氨溴索联合雾化吸入治疗AECOPD疗效肯定,且无明显副作用。
OBJECTIVE: To observe the clinical efficacy of combination of BoliCan, budesonide and ambroxol in the treatment of acute exacerbation of obstructive pulmonary disease (AECPD). Methods: 72 AECPD patients were randomly divided into two groups, the treatment group and the control group of 36 cases. The treatment group was given Gaborconconazole, budesonide and ambroxol combined with oxygen-driven aerosol inhalation on the basis of the treatment of oxygen and anti-infection, twice a day; the control group was treated with oxygen and anti-infection Boli Kang Ni, ambroxol oral. Record two groups of patients medication cough, shortness of breath or wheezing, sputum and other changes in the 7 days before and after treatment. Results: There was significant difference between the two groups (P <0.05). Conclusion: The effect of combination of BoliCane, budesonide and ambroxol in the treatment of AECOPD is definite and has no obvious side effects.